Avalo Therapeutics, Inc. current report, 21 April 2020

Business Context and Reporting Period

This Form 8-K filing by Cerecor Inc. (CERC) reports significant corporate governance and executive leadership changes effective April 24, 2020. The report details the appointment of an Interim Chief Financial Officer, the resignation of the former CFO, the appointment of two new directors, and the separation of a former executive who will transition to a special advisor role.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.

Material Changes and Executive Actions

  • Appointment of Interim CFO: Christopher Sullivan was appointed Interim Chief Financial Officer, effective April 24, 2020. He previously served as Vice President of Finance.
  • Resignation of CFO: Joseph Miller resigned as Chief Financial Officer effective April 24, 2020. The resignation was not related to any disagreement regarding operations, policies, or practices.
  • Board Appointments: Suzanne Bruhn, Ph.D., and Joseph Miller (the former CFO) were appointed to the Board of Directors effective immediately, serving until the 2020 Annual Meeting.
  • Leadership Transition: Sol Barer, a current director, was appointed Chairman of the Board effective April 24, 2020.
  • Executive Separation: Simon Pedder resigned as an employee effective April 24, 2020, and will not stand for re-election to the Board. He will serve as a special advisor for up to 18 months following the 2020 Annual Meeting.

Compensation and Agreements

Christopher Sullivan (Interim CFO):

  • Base salary increased to $250,000 per year.
  • Retention bonus of $125,000 payable at the six-month anniversary of his appointment.
  • Severance provisions include 12 months of base salary and prorated bonus if terminated without "Cause" or for "Good Reason."

Simon Pedder (Separation):

  • Will receive payments totaling $840,000 at the end of the 18-month consulting period, payable over 18 months.
  • Expedited vesting of time-based equity grants that would have vested within 18 months after the consulting period ends.
  • Extension of the exercise term for all outstanding equity grants to two years following the end of the consulting period.
  • Forfeiture of stock options with vesting based on share price as of the termination date.

Investor Verification Checklist

  • Verify the impact of the CFO transition on the company's financial reporting timeline and internal controls.
  • Review the full text of the Separation Agreement (Exhibit 10.3) to understand the specific conditions of the $840,000 payment to Simon Pedder.
  • Confirm the qualifications and independence status of the new directors, Suzanne Bruhn and Joseph Miller.
  • Monitor the company's capital position given the retention bonus and severance obligations outlined in the filing.